Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:38 PM
Ignite Modification Date:
2025-12-24 @ 11:38 PM
NCT ID:
NCT04370756
Eligibility Criteria:
Inclusion Criteria:
* Post-menopausal women (self-report)
* Between the ages of 18-75 years (confirmed by birth date listed on participant's driver license at screening visit)
* Physician's clearance for study participation (required prior to baseline testing)
* English-speaking
* Body mass index between 25.0 to 39.9 kg/m\^2 (measured on-site at screening visit)
* Able to ambulate without assistance
Exclusion Criteria:
* Unable to provide informed consent
* 18-75 of age (confirmed by birth date listed on participant's driver license at screening visit)
* Body mass index \< 25.0 or \>39.9 kg/m\^2 (measured on-site at screening visit)
* Greater than stage II hypertension (i.e. \>159/99 mm Hg)
* Current smoker (self-report)
* Currently pregnant, lactating, or trying to become pregnant (self-report)
* Habitually exercise training \>= 3 times per week (self-report)
* Significant orthopedic limitations or other contraindications to strenuous exercise
* Live or work \>50 miles from Bloomington study site or do not have transportation to the study site
* Anticipate elective surgery during the study period
* Plan to move residence or travel out of the local area during the study period
* History of major metabolic disease (e.g. Type I diabetes, Type II diabetes, thyroid disorders)
* Current use of anti-coagulants (e.g. Coumadin or Warfarin)
* Current use of prescription medications that affect heart rate or blood vessel dilation (e.g. phosphodiesterase-5 inhibitors, proton pump inhibitors, systemic adrenergic blockers, nitrates, calcium channel blockers, hormone replacement therapy) (self-report and confirmed on-site at screening visit)
* Psychological or social characteristic that would interfere with their ability to fully participate in the study (i.e. taking longer than allowed time to complete cognitive assessments)
Healthy Volunteers:
True
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT04370756
Study Brief:
Protocol Section:
NCT04370756